000856857 001__ 856857
000856857 005__ 20210129235418.0
000856857 0247_ $$2doi$$a10.1128/AAC.01146-18
000856857 0247_ $$2ISSN$$a0066-4804
000856857 0247_ $$2ISSN$$a1070-6283
000856857 0247_ $$2ISSN$$a1098-6596
000856857 0247_ $$2Handle$$a2128/21836
000856857 0247_ $$2pmid$$apmid:30348662
000856857 0247_ $$2WOS$$aWOS:000454140200008
000856857 0247_ $$2altmetric$$aaltmetric:50261949
000856857 037__ $$aFZJ-2018-06196
000856857 082__ $$a610
000856857 1001_ $$0P:(DE-HGF)0$$aTanabe, Koichi$$b0
000856857 245__ $$aFK506 resistance of Saccharomyces cerevisiae Pdr5 and Candida albicans Cdr1 involves mutations in the transmembrane domains and extracellular loops
000856857 260__ $$aWashington, DC$$bSoc.$$c2019
000856857 3367_ $$2DRIVER$$aarticle
000856857 3367_ $$2DataCite$$aOutput Types/Journal article
000856857 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1552470740_13869
000856857 3367_ $$2BibTeX$$aARTICLE
000856857 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000856857 3367_ $$00$$2EndNote$$aJournal Article
000856857 520__ $$aThe 23-membered-ring macrolide tacrolimus, a commonly used immunosuppressant, also known as FK506, is a broad-spectrum inhibitor and an efflux pump substrate of pleiotropic drug resistance (PDR) ATP-binding cassette (ABC) transporters. Little, however, is known about the molecular mechanism by which FK506 inhibits PDR transporter drug efflux. Thus, to obtain further insights we searched for FK506-resistant mutants of Saccharomyces cerevisiae cells overexpressing either the endogenous multidrug efflux pump, Pdr5, or its Candida albicans orthologue, Cdr1. A simple, but powerful, screen gave 69 FK506-resistant mutants with, between them, 72 mutations in either Pdr5 (37) or Cdr1 (35). Twenty mutations were in just three Pdr5/Cdr1 equivalent amino acid positions T550/T540 and T552/S542 of extracellular loop 1 (EL1) and A723/A713 of EL3. Sixty of the 72 mutations were either in the ELs or the extracellular halves of individual transmembrane spans (TMSs), while 11 mutations were found near the centre of individual TMSs, mostly in predicted TMS-TMS contact points, and only two mutations were in the cytosolic nucleotide-binding domains of Pdr5. We propose that FK506 inhibits Pdr5 and Cdr1 drug efflux by slowing transporter opening and/or substrate release, and that FK506-resistance of Pdr5/Cdr1 drug efflux is achieved by modifying critical intramolecular contact points that, when mutated, enable the co-transport of FK506 with other pump substrates. This may also explain why the 35 Cdr1 mutations that caused FK506-insensitivity of fluconazole efflux differed from the 13 Cdr1 mutations that caused FK506-insensitivity of cycloheximide efflux.
000856857 536__ $$0G:(DE-HGF)POF3-511$$a511 - Computational Science and Mathematical Methods (POF3-511)$$cPOF3-511$$fPOF III$$x0
000856857 536__ $$0G:(DE-Juel1)hkf7_20170501$$aForschergruppe Gohlke (hkf7_20170501)$$chkf7_20170501$$fForschergruppe Gohlke$$x1
000856857 588__ $$aDataset connected to CrossRef
000856857 7001_ $$0P:(DE-HGF)0$$aBonus, Michele$$b1
000856857 7001_ $$0P:(DE-HGF)0$$aTomiyama, Susumu$$b2
000856857 7001_ $$0P:(DE-HGF)0$$aMiyoshi, Kunji$$b3
000856857 7001_ $$0P:(DE-HGF)0$$aNagi, Minoru$$b4
000856857 7001_ $$0P:(DE-HGF)0$$aNiimi, Kyoko$$b5
000856857 7001_ $$0P:(DE-HGF)0$$aChindamporn, Ariya$$b6
000856857 7001_ $$0P:(DE-Juel1)172663$$aGohlke, Holger$$b7$$ufzj
000856857 7001_ $$0P:(DE-HGF)0$$aSchmitt, Lutz$$b8
000856857 7001_ $$0P:(DE-HGF)0$$aCannon, Richard D.$$b9
000856857 7001_ $$0P:(DE-HGF)0$$aNiimi, Masakazu$$b10$$eCorresponding author
000856857 7001_ $$0P:(DE-HGF)0$$aLamping, Erwin$$b11$$eCorresponding author
000856857 773__ $$0PERI:(DE-600)1496156-8$$a10.1128/AAC.01146-18$$gp. AAC.01146-18aac;AAC.01146-18v1$$n1$$pe01146-18$$tAntimicrobial agents and chemotherapy$$v63$$x1098-6596$$y2019
000856857 8564_ $$uhttps://juser.fz-juelich.de/record/856857/files/Clean%20copy%20of%20revision1-1.pdf$$yPublished on 2018-12-21. Available in OpenAccess from 2019-06-21.
000856857 909CO $$ooai:juser.fz-juelich.de:856857$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000856857 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)172663$$aForschungszentrum Jülich$$b7$$kFZJ
000856857 9131_ $$0G:(DE-HGF)POF3-511$$1G:(DE-HGF)POF3-510$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lSupercomputing & Big Data$$vComputational Science and Mathematical Methods$$x0
000856857 9141_ $$y2019
000856857 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000856857 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000856857 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000856857 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANTIMICROB AGENTS CH : 2017
000856857 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000856857 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000856857 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000856857 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000856857 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000856857 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000856857 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000856857 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000856857 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000856857 920__ $$lyes
000856857 9201_ $$0I:(DE-Juel1)JSC-20090406$$kJSC$$lJülich Supercomputing Center$$x0
000856857 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie $$x1
000856857 9201_ $$0I:(DE-Juel1)NIC-20090406$$kNIC$$lJohn von Neumann - Institut für Computing$$x2
000856857 9801_ $$aFullTexts
000856857 980__ $$ajournal
000856857 980__ $$aVDB
000856857 980__ $$aUNRESTRICTED
000856857 980__ $$aI:(DE-Juel1)JSC-20090406
000856857 980__ $$aI:(DE-Juel1)ICS-6-20110106
000856857 980__ $$aI:(DE-Juel1)NIC-20090406
000856857 981__ $$aI:(DE-Juel1)IBI-7-20200312